{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:44:13Z","timestamp":1788983053040,"version":"build-2803163510"},"reference-count":207,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The introduction of BTK inhibitors and BCL2 antagonists to the treatment of chronic lymphocytic leukemia (CLL) has revolutionized therapy and improved patient outcomes. These agents have replaced chemoimmunotherapy as standard of care. Despite this progress, a new group of patients is currently emerging, which has become refractory or intolerant to both classes of agents, creating an unmet medical need. Here, we propose that the targeted modulation of the tumor microenvironment provides new therapeutic options for this group of double-refractory patients. Furthermore, we outline a sequential strategy for tumor microenvironment-directed combination therapies in CLL that can be tested in clinical protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023022861","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:56:54Z","timestamp":1716393414000},"page":"601-614","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-6703","authenticated-orcid":false,"given":"Richard I.","family":"Lewis","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, Faculty of Medicine, University of Cologne, University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Center for Molecular Medicine Cologne, CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-7792","authenticated-orcid":false,"given":"Alexander F.","family":"vom Stein","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Faculty of Medicine, University of Cologne, University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Center for Molecular Medicine Cologne, CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Faculty of Medicine, University of Cologne, University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Center for Molecular Medicine Cologne, CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2024080815203668800_bib1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024080815203668800_bib2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024080815203668800_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"36","key":"2024080815203668800_bib4","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024080815203668800_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024080815203668800_bib6","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2024080815203668800_bib7","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/HS9.0000000000000287","article-title":"Minimal residual disease assessment in CLL: ready for use in clinical routine?","volume":"3","author":"Furstenau","year":"2019","journal-title":"Hemasphere"},{"issue":"1","key":"2024080815203668800_bib8","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"2024080815203668800_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2024080815203668800_bib10","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"2024080815203668800_bib11","first-page":"S19","article-title":"Approach to a patient with \u201cdouble refractory\u201d chronic lymphocytic leukemia: \u201cdouble, double toil and trouble\u201d (Shakespeare)","volume":"97","author":"Aronson","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2024080815203668800_bib12","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"22","key":"2024080815203668800_bib13","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024080815203668800_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2024080815203668800_bib15","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2024080815203668800_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","volume":"199","author":"Hampel","year":"2022","journal-title":"Br J Haematol"},{"issue":"suppl1","key":"2024080815203668800_bib17","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1182\/blood-2023-187129","article-title":"Clinical outcomes in patients treated with both covalent Btkis and venetoclax and the significance of \u201cdouble-refractory\u201d status in patients with CLL\/SLL","volume":"142","author":"Samples","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2024080815203668800_bib18","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/bloodadvances.2022007708","article-title":"Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes","volume":"6","author":"Hyak","year":"2022","journal-title":"Blood Adv"},{"issue":"31","key":"2024080815203668800_bib19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024080815203668800_bib20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024080815203668800_bib21","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2022-167583","article-title":"Tolerability of acalabrutinib after prior ibrutinib treatment in patients with CLL: experience of a Tertiary Cancer Care Center","volume":"140","author":"DiPippo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024080815203668800_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"9747","key":"2024080815203668800_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"2024080815203668800_bib24","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024080815203668800_bib25","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024080815203668800_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2024080815203668800_bib27","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024080815203668800_bib28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematology"},{"issue":"13","key":"2024080815203668800_bib29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024080815203668800_bib30","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024080815203668800_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024080815203668800_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024080815203668800_bib33","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024080815203668800_bib34","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2024080815203668800_bib35","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2024080815203668800_bib36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"17","key":"2024080815203668800_bib37","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2020003944","article-title":"Extrinsic interactions in the microenvironment in\u00a0vivo activate an antiapoptotic multidrug-resistant phenotype in CLL","volume":"5","author":"Jayappa","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2024080815203668800_bib38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"issue":"526","key":"2024080815203668800_bib39","doi-asserted-by":"crossref","first-page":"eaax9340","DOI":"10.1126\/scitranslmed.aax9340","article-title":"Stromal cell protein kinase C-beta inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"issue":"5","key":"2024080815203668800_bib40","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13492","article-title":"Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML","volume":"105","author":"Hormi","year":"2020","journal-title":"Eur J Haematol"},{"issue":"13","key":"2024080815203668800_bib41","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024080815203668800_bib42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","article-title":"Safety and efficacy of navitoclax, a BCL-2 and BCL-X(L) inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study","volume":"62","author":"de Vos","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2024080815203668800_bib43","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood.2021014760","article-title":"ROR1: an orphan becomes apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024080815203668800_bib44","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","volume":"36","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"2024080815203668800_bib45","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"16 suppl","key":"2024080815203668800_bib46","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2022.40.16_suppl.7520","article-title":"Phase 1\/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)","volume":"40","author":"Lee","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024080815203668800_bib47","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2023-188607","article-title":"Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)","volume":"142","author":"Townsend","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024080815203668800_bib48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2023.12.004","article-title":"Role of the tumor microenvironment in CLL pathogenesis","volume":"61","author":"Vom Stein","year":"2024","journal-title":"Semin Hematol"},{"key":"2024080815203668800_bib49","doi-asserted-by":"crossref","first-page":"612244","DOI":"10.3389\/fimmu.2020.612244","article-title":"T\u00a0cells in chronic lymphocytic leukemia: a two-edged sword","volume":"11","author":"Vlachonikola","year":"2020","journal-title":"Front Immunol"},{"issue":"14","key":"2024080815203668800_bib50","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.2021013926","article-title":"Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib","volume":"139","author":"Purroy","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024080815203668800_bib51","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T\u00a0cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2024080815203668800_bib52","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2016.214","article-title":"The PD-1\/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia","volume":"31","author":"Qorraj","year":"2017","journal-title":"Leukemia"},{"issue":"10304","key":"2024080815203668800_bib53","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"2024080815203668800_bib54","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024080815203668800_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2024080815203668800_bib56","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2024080815203668800_bib57","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1182\/blood-2023-181624","article-title":"Multifactorial basis of T cell dysfunction in CLL: disrupted mitochondrial metabolism induces T cell senescence","volume":"142","author":"Goedhart","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024080815203668800_bib58","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41375-023-01817-z","article-title":"Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors","volume":"37","author":"Martens","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2024080815203668800_bib59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2024080815203668800_bib60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"21","key":"2024080815203668800_bib61","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1182\/bloodadvances.2023010305","article-title":"T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia","volume":"7","author":"Montironi","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024080815203668800_bib62","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice","volume":"106","author":"Hanna","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"2024080815203668800_bib63","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"2024080815203668800_bib64","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A\u00a0phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024080815203668800_bib65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"2024080815203668800_bib66","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.tranon.2021.101116","article-title":"Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade","volume":"14","author":"Li","year":"2021","journal-title":"Transl Oncol"},{"issue":"1","key":"2024080815203668800_bib67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2024080815203668800_bib68","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1182\/blood-2021-154195","article-title":"Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for first-line treatment for patients with chronic lymphocytic leukemia (CLL)","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2024080815203668800_bib69","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10306","key":"2024080815203668800_bib70","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2024080815203668800_bib71","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A\u00a0CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024080815203668800_bib72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"2024080815203668800_bib73","author":"Kater","year":"6-9  2023"},{"issue":"15","key":"2024080815203668800_bib74","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv"},{"issue":"7897","key":"2024080815203668800_bib75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"5","key":"2024080815203668800_bib76","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/curroncol29050293","article-title":"CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings","volume":"29","author":"Todorovic","year":"2022","journal-title":"Curr Oncol"},{"issue":"4","key":"2024080815203668800_bib77","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3Kdelta\/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2024080815203668800_bib78","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2024080815203668800_bib79","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2024080815203668800_bib80","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/cas.14915","article-title":"Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma","volume":"112","author":"Liu","year":"2021","journal-title":"Cancer Sci"},{"issue":"9","key":"2024080815203668800_bib81","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"2024080815203668800_bib82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"2024080815203668800_bib83","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cells10020217","article-title":"Nurse-like cells and chronic lymphocytic leukemia B cells: a mutualistic crosstalk inside tissue microenvironments","volume":"10","author":"Fiorcari","year":"2021","journal-title":"Cells"},{"issue":"8","key":"2024080815203668800_bib84","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell\u2013derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2024080815203668800_bib85","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2024080815203668800_bib86","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1\u03b1","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2024080815203668800_bib87","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/bcj.2015.108","article-title":"Nurse-like cells impact on disease progression in chronic lymphocytic leukemia","volume":"6","author":"Boissard","year":"2016","journal-title":"Blood Cancer J"},{"issue":"11","key":"2024080815203668800_bib88","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood-2013-10-529610","article-title":"Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia","volume":"123","author":"Jia","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024080815203668800_bib89","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in\u00a0vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2024080815203668800_bib90","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","article-title":"Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression","volume":"14","author":"Galletti","year":"2016","journal-title":"Cell Rep"},{"issue":"9","key":"2024080815203668800_bib91","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.20101157","article-title":"Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums","volume":"207","author":"Ravichandran","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"2024080815203668800_bib92","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1172\/JCI70972","article-title":"The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging","volume":"123","author":"Montalvao","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2024080815203668800_bib93","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI66776","article-title":"Macrophages eliminate circulating tumor cells after monoclonal antibody therapy","volume":"124","author":"Gul","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2024080815203668800_bib94","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"17","key":"2024080815203668800_bib95","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2024080815203668800_bib96","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16 suppl","key":"2024080815203668800_bib97","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/JCO.2022.40.16_suppl.7020","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results","volume":"40","author":"Daver","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024080815203668800_bib98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-022-00279-w","article-title":"CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model","volume":"11","author":"Chauchet","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"2024080815203668800_bib99","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2018-99-110181","article-title":"The fully human anti-CD47 antibody SRF231 has dual-mechanism antitumor activity against chronic lymphocytic leukemia (CLL) cells and increases the activity of both rituximab and venetoclax","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"key":"2024080815203668800_bib100","doi-asserted-by":"crossref","first-page":"929339","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"2024080815203668800_bib101","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/2326-6066.CIR-17-0537","article-title":"Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"12 suppl","key":"2024080815203668800_bib102","article-title":"Phase I study of IBI322 (anti-CD47\/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"issue":"2","key":"2024080815203668800_bib103","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"2024080815203668800_bib104","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.3390\/ijms22136665","article-title":"NK cells in chronic lymphocytic leukemia and their therapeutic implications","volume":"22","author":"Sportoletti","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"42","key":"2024080815203668800_bib105","doi-asserted-by":"crossref","first-page":"68513","DOI":"10.18632\/oncotarget.12097","article-title":"NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma","volume":"7","author":"Parry","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"2024080815203668800_bib106","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.179.3.999","article-title":"Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells","volume":"179","author":"Lotz","year":"1994","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"2024080815203668800_bib107","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/cncr.30427","article-title":"HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia","volume":"123","author":"Wagner","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"2024080815203668800_bib108","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/leu.2008.15","article-title":"NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G","volume":"22","author":"Maki","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2024080815203668800_bib109","doi-asserted-by":"crossref","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","article-title":"Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia","volume":"5","author":"McWilliams","year":"2016","journal-title":"Oncoimmunology"},{"issue":"6","key":"2024080815203668800_bib110","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/HS9.0000000000000308","article-title":"Natural killer cell hypo-responsiveness in chronic lymphocytic leukemia can be circumvented in\u00a0vitro by adequate activating signaling","volume":"3","author":"Hofland","year":"2019","journal-title":"Hemasphere"},{"issue":"3","key":"2024080815203668800_bib111","doi-asserted-by":"crossref","first-page":"e20200839","DOI":"10.1084\/jem.20200839","article-title":"The SIRP\u03b1\u2013CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J\u00a0Exp Med"},{"key":"2024080815203668800_bib112","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"2024080815203668800_bib113","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024080815203668800_bib114","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024080815203668800_bib115","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","article-title":"Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers","volume":"43","author":"Pinto","year":"2022","journal-title":"Trends Immunol"},{"issue":"12","key":"2024080815203668800_bib116","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2024080815203668800_bib117","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fonc.2020.01422","article-title":"Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles","volume":"10","author":"Dubois","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2024080815203668800_bib118","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1158\/2159-8290.CD-14-0096","article-title":"Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation","volume":"4","author":"Heinig","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"2024080815203668800_bib119","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2012.12.003","article-title":"Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in\u00a0vivo","volume":"23","author":"Lutzny","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"2024080815203668800_bib120","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2024080815203668800_bib121","doi-asserted-by":"crossref","first-page":"e001889","DOI":"10.1136\/jitc-2020-001889","article-title":"Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis","volume":"9","author":"B\u00f6ttcher","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2024080815203668800_bib122","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41467-023-36824-2","article-title":"LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1","volume":"14","author":"vom Stein","year":"2023","journal-title":"Nat Commun"},{"issue":"26","key":"2024080815203668800_bib123","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"issue":"7693","key":"2024080815203668800_bib124","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"2024080815203668800_bib125","doi-asserted-by":"crossref","first-page":"104380","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGFbeta and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"EBioMedicine"},{"issue":"3","key":"2024080815203668800_bib126","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment","volume":"1863","author":"Ten Hacken","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"19","key":"2024080815203668800_bib127","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1182\/bloodadvances.2022008207","article-title":"Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia","volume":"7","author":"Parvin","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2024080815203668800_bib128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv"},{"issue":"14","key":"2024080815203668800_bib129","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1080\/10428194.2019.1643463","article-title":"A\u00a0multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia","volume":"60","author":"Andritsos","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2024080815203668800_bib130","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3390\/cancers12102725","article-title":"Neutralization of B-cell activating factor (BAFF) by belimumab reinforces small molecule inhibitor treatment in chronic lymphocytic leukemia","volume":"12","author":"Tandler","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2024080815203668800_bib131","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2024080815203668800_bib132","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41375-018-0366-8","article-title":"New roles for B cell receptor associated kinases: when the B cell is not the target","volume":"33","author":"Nguyen","year":"2019","journal-title":"Leukemia"},{"issue":"15","key":"2024080815203668800_bib133","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"2024080815203668800_bib134","doi-asserted-by":"crossref","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2024080815203668800_bib135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2024080815203668800_bib136","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol Oncol"},{"issue":"21","key":"2024080815203668800_bib137","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL Vgamma9Vdelta2-T-cell fitness for cellular therapy by ex\u00a0vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2024080815203668800_bib138","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"issue":"7629","key":"2024080815203668800_bib139","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"7629","key":"2024080815203668800_bib140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"issue":"8","key":"2024080815203668800_bib141","doi-asserted-by":"crossref","first-page":"e002279","DOI":"10.1136\/jitc-2020-002279","article-title":"Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal","volume":"9","author":"Isoyama","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"2024080815203668800_bib142","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024080815203668800_bib143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2013.10.004","article-title":"Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study","volume":"38","author":"Kater","year":"2014","journal-title":"Leuk Res"},{"issue":"9","key":"2024080815203668800_bib144","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2024080815203668800_bib145","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood.V118.21.2858.2858","article-title":"A\u00a0pilot phase II study of the Lyn kinase inhibitor bafetinib in patients with relapsed or refractory B cell chronic lymphocytic leukemia","volume":"118","author":"Kadia","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2024080815203668800_bib146","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","article-title":"LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia","volume":"30","author":"Nguyen","year":"2016","journal-title":"Cancer Cell"},{"issue":"8","key":"2024080815203668800_bib147","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"issue":"13","key":"2024080815203668800_bib148","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","article-title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches","volume":"112","author":"Hallaert","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2024080815203668800_bib149","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"499","key":"2024080815203668800_bib150","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"issue":"5","key":"2024080815203668800_bib151","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2024080815203668800_bib152","doi-asserted-by":"crossref","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"2024080815203668800_bib153","doi-asserted-by":"crossref","first-page":"e002582","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"2024080815203668800_bib154","doi-asserted-by":"crossref","first-page":"e001496","DOI":"10.1136\/jitc-2020-001496","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation","volume":"9","author":"Redin","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"2024080815203668800_bib155","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"6537","key":"2024080815203668800_bib156","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"6","key":"2024080815203668800_bib157","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2022.282005","article-title":"Differential inhibition of T cell receptor and STAT5 signalling pathways determines the\u00a0immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia","volume":"108","author":"Harrington","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2024080815203668800_bib158","doi-asserted-by":"crossref","first-page":"E916","DOI":"10.1002\/ijc.27537","article-title":"Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib","volume":"131","author":"Hassold","year":"2012","journal-title":"Int J Cancer"},{"issue":"3","key":"2024080815203668800_bib159","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hon.2034","article-title":"Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in\u00a0vitro\u00a0study","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Hematol Oncol"},{"issue":"3","key":"2024080815203668800_bib160","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/pharmaceutics15030917","article-title":"Immunomodulatory activity of the tyrosine kinase inhibitor dasatinib to elicit NK cytotoxicity against cancer, HIV infection and aging","volume":"15","author":"Rodriguez-Agustin","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"2024080815203668800_bib161","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1097\/HS9.0000000000000692","article-title":"Efficacy and safety of the combination of tirabrutinib and entospletinib with or without obinutuzumab in relapsed chronic lymphocytic leukemia","volume":"6","author":"Kutsch","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2024080815203668800_bib162","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/10428194.2018.1562180","article-title":"Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study","volume":"60","author":"Awan","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024080815203668800_bib163","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2024080815203668800_bib164","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2017.170571","article-title":"SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia","volume":"102","author":"Paiva","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2024080815203668800_bib165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-016-1946-y","article-title":"The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients","volume":"66","author":"Colado","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2024080815203668800_bib166","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00262-021-03043-x","article-title":"Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype","volume":"71","author":"Elias","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"34","key":"2024080815203668800_bib167","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024080815203668800_bib168","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"2024080815203668800_bib169","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.leukres.2016.05.012","article-title":"Results of a phase II study of lenalidomide and rituximab for refractory\/relapsed chronic lymphocytic leukemia","volume":"47","author":"Chavez","year":"2016","journal-title":"Leuk Res"},{"issue":"6","key":"2024080815203668800_bib170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1470-2045(06)70723-9","article-title":"Immunomodulating drugs for chronic lymphocytic leukaemia","volume":"7","author":"Chanan-Khan","year":"2006","journal-title":"Lancet Oncol"},{"issue":"21","key":"2024080815203668800_bib171","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2024080815203668800_bib172","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2014.113217","article-title":"Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia","volume":"100","author":"Fiorcari","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"2024080815203668800_bib173","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood.V124.21.3286.3286","article-title":"Lenalidomide promotes a pro-inflammatory switch of nurse-like cells derived from chronic lymphocytic leukemia","volume":"124","author":"Maffei","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2024080815203668800_bib174","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood-2012-08-447664","article-title":"Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment","volume":"121","author":"Schulz","year":"2013","journal-title":"Blood"},{"issue":"16","key":"2024080815203668800_bib175","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of B cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"23","key":"2024080815203668800_bib176","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1182\/bloodadvances.2021005400","article-title":"An autologous culture model of nodal B-cell lymphoma identifies ex\u00a0vivo determinants of response to bispecific antibodies","volume":"5","author":"Roider","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2024080815203668800_bib177","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024080815203668800_bib178","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"key":"2024080815203668800_bib179","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-019-0166-y","article-title":"Targeted therapies for myeloproliferative neoplasms","volume":"7","author":"Li","year":"2019","journal-title":"Biomark Res"},{"issue":"19","key":"2024080815203668800_bib180","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024080815203668800_bib181","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(16)30194-6","article-title":"Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial","volume":"4","author":"Jain","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"2024080815203668800_bib182","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2024080815203668800_bib183","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1002\/cam4.4378","article-title":"Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: results of a phase II trial","volume":"10","author":"Spaner","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"2024080815203668800_bib184","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2024080815203668800_bib185","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and chronic lymphocytic leukemia: a decade later","volume":"118","author":"Malavasi","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2024080815203668800_bib186","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-18-3412","article-title":"Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia","volume":"25","author":"Manna","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2024080815203668800_bib187","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1182\/blood-2022-163096","article-title":"Combined treatment with ibrutinib and anti-CD38 monoclonal antibody daratumumab in relapsed\/refractory chronic lymphocytic leukemia with TP53 aberrations: results of the Filo Phase II Study IDA53","volume":"140","author":"Aurran-Schleinitz","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024080815203668800_bib188","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia","volume":"23","author":"Matas-Cespedes","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024080815203668800_bib189","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2024080815203668800_bib190","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"2024080815203668800_bib191","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"13","key":"2024080815203668800_bib192","doi-asserted-by":"crossref","first-page":"e166070","DOI":"10.1172\/JCI166070","article-title":"Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma","volume":"133","author":"Apollonio","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"19","key":"2024080815203668800_bib193","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2024080815203668800_bib194","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024080815203668800_bib195","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2024080815203668800_bib196","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7762","key":"2024080815203668800_bib197","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"},{"issue":"21","key":"2024080815203668800_bib198","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2024080815203668800_bib199","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"issue":"19","key":"2024080815203668800_bib200","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","article-title":"Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib, and venetoclax","volume":"28","author":"Furstenau","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024080815203668800_bib201","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T\u00a0cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"issue":"18","key":"2024080815203668800_bib202","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-19-3827","article-title":"T-cell dynamics in chronic lymphocytic leukemia under different treatment modalities","volume":"26","author":"Vardi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2024080815203668800_bib203","doi-asserted-by":"crossref","first-page":"e26011","DOI":"10.4161\/onci.26011","article-title":"Monitoring NK cell activity in patients with hematological malignancies","volume":"2","author":"Viel","year":"2013","journal-title":"Oncoimmunology"},{"issue":"1","key":"2024080815203668800_bib204","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1186\/s12885-019-5971-z","article-title":"Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia","volume":"19","author":"Gauthier","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"2024080815203668800_bib205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.16260","article-title":"Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL","volume":"188","author":"Elston","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2024080815203668800_bib206","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J\u00a0Immunol"},{"issue":"21","key":"2024080815203668800_bib207","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.3390\/ijms21218112","article-title":"Assessment of NK cell activity based on NK cell-specific receptor synergy in peripheral blood mononuclear cells and whole blood","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/6\/601\/2237341\/blood_bld-2023-022861-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/6\/601\/2237341\/blood_bld-2023-022861-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T11:22:25Z","timestamp":1723116145000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/6\/601\/516187\/Targeting-the-tumor-microenvironment-for-treating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":207,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022861","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}